

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (original) An isolated antibody, or an antigen-binding portion thereof, that dissociates from human erythropoietin receptor (EpoR) with a  $K_{off}$  rate constant of greater than about  $1.3 \times 10^{-3} \text{ s}^{-1}$  and that activates an endogenous activity of said human EpoR in a mammal.

2. (original) The antibody or antigen-binding portion thereof of claim 1 wherein said  $K_{off}$  rate constant is about  $1.4 \times 10^{-3} \text{ s}^{-1}$  or greater.

3. (original) The antibody or antigen-binding portion thereof of claim 1 wherein said  $K_{off}$  rate constant is about  $1.9 \times 10^{-3} \text{ s}^{-1}$ .

4. (original) The antibody or antigen-binding portion of claim 1 wherein said  $K_{off}$  rate constant is about  $4.8 \times 10^{-3} \text{ s}^{-1}$ .

5. (original) The antibody or antigen-binding portion of claim 1 wherein said  $K_{off}$  rate constant is determined by surface plasmon resonance.

6. (original) The antibody or antigen-binding portion thereof of claim 1 wherein said antibody is a monoclonal antibody.

7.(original) The antibody or antigen-binding portion thereof of claim 6 wherein said antibody is an IgG2 isotype.

8. (original) The antibody or antigen-binding portion thereof of claim 1 that binds to human EpoR with a  $K_d$  of about 7 nM or greater.

9. (original) The antibody or antigen-binding portion thereof of claim 8 wherein said  $K_d$  is about 8.5 nM or greater.

10. (original) The antibody or antigen-binding portion thereof of claim 8 wherein said  $K_d$  is about 20 nM.

11. (original) The antibody or antigen-binding portion thereof of claim 8 wherein said  $K_d$  is about 32 nM.

12. (original) The antibody or antigen-binding portion thereof of claim 8 wherein said  $K_d$  is about 7-32 nM inclusive.

13. (original) The antibody or antigen-binding portion thereof of claim 1 which is a human antibody.

14. (original) An antibody or antigen-binding portion thereof that activates an endogenous activity of a human erythropoietin receptor in a mammal comprising a heavy chain variable region (HCVR) comprising an amino acid sequence of Formula I:

**Y-I-X<sub>1</sub>-X<sub>2</sub>-X<sub>3</sub>-G-S-T-N-Y-N-P-S-L-K-S (SEQ ID NO:18)**

wherein:

X<sub>1</sub> is independently selected from the group consisting of tyrosine (Y), glycine (G) and alanine (A);

X<sub>2</sub> is independently selected from the group consisting of tyrosine (Y), glycine (G), alanine (A), glutamine (E) and aspartic acid (D); and

X<sub>3</sub> is independently selected from the group consisting of serine (S), glycine (G), glutamine (E) and threonine (T)

with the proviso that X1-X2-X3 is other than Y-Y-S.

15. (original) The antibody or antigen-binding portion thereof of claim 14 wherein X<sub>1</sub> is G and X<sub>2</sub> and X<sub>3</sub> are as defined therein.

16. (original) The antibody or antigen-binding portion thereof of claim 14 wherein X<sub>2</sub> is G and X<sub>1</sub> and X<sub>3</sub> are as defined therein.

17. (original) The antibody or antigen-binding portion thereof of claim 14 wherein X<sub>3</sub> is E and X<sub>1</sub> and X<sub>2</sub> are as defined therein.

18. (original) The antibody or antigen-binding portion thereof of claim 14 wherein X<sub>1</sub> is G, X<sub>2</sub> is G and X<sub>3</sub> is as defined therein.

19. (original) The antibody or antigen-binding portion thereof of claim 14 wherein X<sub>1</sub> is as defined therein, X<sub>2</sub> is G and X<sub>3</sub> is E.

20. (original) The antibody or antigen-binding portion thereof of claim 14 wherein X<sub>1</sub> is G, X<sub>2</sub> is G and X<sub>3</sub> is E.

21. (original) The antibody or antigen-binding portion thereof of claim 14 wherein X<sub>1</sub> is A, X<sub>2</sub> is G and X<sub>3</sub> is T.

22. (original) An antibody or antigen-binding portion thereof comprising an amino acid sequence selected from the group consisting of

- (a) YIGGEGSTNYPNPSLKS (SEQ ID NO:19);
- (b) YIAGTGSTNYPNPSLKS (SEQ ID NO:20);
- (c) YIGYSGSTNYPNPSLKS (SEQ ID NO:21);
- (d) YIYGGSTNYPNPSLKS (SEQ ID NO:22);
- (e) YIYYEGSTNYPNPSLKS (SEQ ID NO:23);

- (f) YIGGSGSTNYNPSLKS (SEQ ID NO:24);
- (g) YIYGEGSTNYNPSLKS (SEQ ID NO:25); and
- (h) YIGYEGSTNYNPSLKS (SEQ ID NO:26).

23. (original) A method of activating an endogenous activity of a human erythropoietin receptor in a mammal, the method comprising the step of administering to said mammal a therapeutically effective amount of an antibody or antigen-binding portion thereof of claim 1.

24. (original) A method of activating an endogenous activity of a human erythropoietin receptor in a mammal, the method comprising the step of administering to said mammal a therapeutically effective amount of an antibody or antigen-binding portion thereof of claim 2.

25. (original) A method of modulating an endogenous activity of a human erythropoietin receptor in a mammal, the method comprising the step of administering to said mammal a therapeutically effective amount of an antibody or antigen-binding portion thereof of claim 3.

26. (original) A method of activating an endogenous activity of a human erythropoietin receptor in a mammal, the method comprising the step of administering to said mammal a therapeutically effective amount of an antibody or antigen-binding portion thereof of claim 4.

27. (original) A method of activating an endogenous activity of a human erythropoietin receptor in a mammal, the method comprising the step of administering to said mammal a therapeutically effective amount of an antibody or antigen-binding portion thereof of claim 6.

28. (original) A method of activating an endogenous activity of a human erythropoietin receptor in a mammal, the method comprising the step of administering to said mammal a therapeutically effective amount of an antibody or antigen-binding portion thereof of claim 7.

29. (original) A method of activating an endogenous activity of a human erythropoietin receptor in a mammal, the method comprising the step of administering to said mammal a therapeutically effective amount of an antibody or antigen-binding portion thereof of claim 8.

30. (original) A method of activating an endogenous activity of a human erythropoietin receptor in a mammal, the method comprising the step of administering to said mammal a therapeutically effective amount of an antibody or antigen-binding portion thereof of claim 10.

31. (original) A method of activating an endogenous activity of a human erythropoietin receptor in a mammal, the method comprising the step of administering to said mammal a therapeutically effective amount of an antibody or antigen-binding portion thereof of claim 11.

32. (original) A method of activating an endogenous activity of a human erythropoietin receptor in a mammal, the method comprising the step of administering to said mammal a therapeutically effective amount of an antibody or antigen-binding portion thereof of claim 13.

33. (original) A method of activating an endogenous activity of a human erythropoietin receptor in a mammal, the method comprising the step of administering to said mammal a therapeutically effective amount of an antibody or antigen-binding portion thereof of claim 14.

34. (original) A method of activating an endogenous activity of a human erythropoietin receptor in a mammal, the method comprising the step of administering to said mammal a therapeutically effective amount of an antibody or antigen-binding portion thereof of claim 15, 16, 17, 18, 19, 20 or claim 21.

35. (original) A method of activating an endogenous activity of a human erythropoietin receptor in a mammal, the method comprising the step of administering to said mammal a therapeutically effective amount of an antibody or antigen-binding portion thereof of claim 22.

36. (original) A method of treating a mammal suffering aplasia, the method comprising the step of administering to a mammal in need of treatment a therapeutically effective amount of the antibody or antigen-binding portion thereof of claim 1.

37. (original) A method of treating a mammal suffering aplasia, the method comprising the step of administering to a mammal in need of treatment a therapeutically effective amount of the antibody or antigen-binding portion thereof of claim 13.

38. (original) A method of treating a mammal suffering anemia, the method comprising the step of administering to a mammal in need of treatment a therapeutically effective amount of the antibody or antigen-binding portion thereof of claim 1.

39. (original) A method of treating a mammal suffering anemia, the method comprising the step of administering to a mammal in need of treatment a therapeutically effective amount of the antibody or antigen-binding portion thereof of claim 13.

40. (original) A pharmaceutical composition comprising a therapeutically effective amount of an antibody or antigen-binding portion thereof of claim 1 and a pharmaceutically acceptable excipient.

41. (original) A pharmaceutical composition comprising a therapeutically effective amount of an antibody or antigen-binding portion thereof of claim 13 and a pharmaceutically acceptable excipient.

42. (original) An isolated or purified polynucleotide sequence which encodes a polypeptide comprising an amino acid sequence of Formula I:

**Y-I-X<sub>1</sub>-X<sub>2</sub>-X<sub>3</sub>-G-S-T-N-Y-N-P-S-L-K-S (SEQ ID NO:18)**

wherein:

X<sub>1</sub> is independently selected from the group consisting of tyrosine (Y), glycine (G) and alanine (A);

X<sub>2</sub> is independently selected from the group consisting of tyrosine (Y), glycine (G), alanine (A), glutamine (E) and aspartic acid (D); and

X<sub>3</sub> is independently selected from the group consisting of serine (S), glycine (G), glutamine (E) and threonine (T)

with the proviso that X<sub>1</sub>-X<sub>2</sub>-X<sub>3</sub> is other than Y-Y-S.

43. (original) The polynucleotide of claim 42 wherein X<sub>1</sub> is G and X<sub>2</sub> and X<sub>3</sub> are as defined therein.

44. (original) The polynucleotide of claim 42 wherein X<sub>2</sub> is G and X<sub>1</sub> and X<sub>3</sub> are as defined therein.

45. (original) The polynucleotide of claim 42 wherein X<sub>3</sub> is E and X<sub>1</sub> and X<sub>2</sub> are as defined therein.

46. (original) The polynucleotide of claim 42 wherein  $X_1$  is G,  $X_2$  is G and  $X_3$  is as defined therein.

47. (original) The polynucleotide of claim 42 wherein  $X_1$  is as defined therein,  $X_2$  is G and  $X_3$  is E.

48. (original) The polynucleotide of claim 42 wherein  $X_1$  is G,  $X_2$  is G and  $X_3$  is E.

49. (original) The polynucleotide of claim 42 wherein  $X_1$  is A,  $X_2$  is G and  $X_3$  is T.



50. (original) The polynucleotide of claim 42 selected from the group consisting of  
(a) YIGGEGSTNYNPSLKS (SEQ ID NO:19);  
(b) YIAGTGSTNYNPSLKS (SEQ ID NO:20);  
(c) YIGYSGSTNYNPSLKS (SEQ ID NO:21);  
(d) YIYGSGSTNYNPSLKS (SEQ ID NO:22);  
(e) YIYYEGSTNYNPSLKS (SEQ ID NO:23);  
(f) YIGGSGSTNYNPSLKS (SEQ ID NO:24);  
(g) YIYGEGSTNYNPSLKS (SEQ ID NO:25); and  
(h) YIGYEGSTNYNPSLKS (SEQ ID NO:26).

42. 51. (original) A recombinant expression vector comprising the polynucleotide of claim

52. (original) A host cell comprising the recombinant expression vector of claim 51.

53. (original) The host cell of claim 52 which is a eucaryotic cell.

54. (original) The host cell of claim 52 which is a mammalian cell.

55. (original) The host cell of claim 52 which is yeast cell.

56. (original) The host cell of claim 52 which is a bacterial cell.

57. (original) The host cell of claim 52 which is a CHO cell.

58. (original) The host cell of claim 52 which is a COS cell.

59. (original) The host cell of claim 52 which is an HEK-293 cell.

60. (original) A polypeptide sequence encoded by said polynucleotide sequence of claim 42.

61. (currently amended) A polypeptide molecule comprising a first polypeptide sequence, a second polypeptide sequence, and a linking sequence, wherein:  
said first polypeptide sequence is capable of binding a ligand;  
said second polypeptide sequence is capable of binding a ligand;  
said linking sequence connects said first polypeptide sequence and said second polypeptide sequence to form a single polypeptide chain; and  
wherein said linking sequence comprises one or more amino acid sequences selected from the group consisting of, Gly-Phe-Lys-Asp-Ala-Leu-Lys-Gln-Pro-Met-Pro-Tyr-Ala-Thr-Ser (SEQ ID NO:~~37~~27), Gly-His-Glu-Ala-Ala-Ala-Val-Met-Gln-Val-Gln-Tyr-Pro-Ala-Ser (SEQ ID NO:4), Gly-Pro-Ala-Lys-Glu-Leu-Thr-Pro-Leu-Lys-Glu-Ala-Lys-Val-Ser (SEQ ID NO:3), and Gly-Glu-Asn-Lys-Val-Glu-Tyr-Ala-Pro-Ala-Leu-Met-Ala-Leu-Ser (SEQ ID NO:2).